PL1664050T3 - Neuroprotekcyjne związki bicykliczne i zawierające je kompozycje farmaceutyczne - Google Patents

Neuroprotekcyjne związki bicykliczne i zawierające je kompozycje farmaceutyczne

Info

Publication number
PL1664050T3
PL1664050T3 PL04782733T PL04782733T PL1664050T3 PL 1664050 T3 PL1664050 T3 PL 1664050T3 PL 04782733 T PL04782733 T PL 04782733T PL 04782733 T PL04782733 T PL 04782733T PL 1664050 T3 PL1664050 T3 PL 1664050T3
Authority
PL
Poland
Prior art keywords
pharmaceutical compositions
compositions containing
bicyclic compounds
neuroprotective
neuroprotective bicyclic
Prior art date
Application number
PL04782733T
Other languages
English (en)
Polish (pl)
Inventor
Margaret Anne Brimble
Jian Guan
Frank Sieg
Original Assignee
Neuren Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuren Pharmaceuticals Ltd filed Critical Neuren Pharmaceuticals Ltd
Publication of PL1664050T3 publication Critical patent/PL1664050T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL04782733T 2003-09-03 2004-08-31 Neuroprotekcyjne związki bicykliczne i zawierające je kompozycje farmaceutyczne PL1664050T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49995603P 2003-09-03 2003-09-03
EP04782733.2A EP1664050B1 (en) 2003-09-03 2004-08-31 Neuroprotective bicyclic compounds and pharmaceutical compositions containing them
PCT/US2004/028308 WO2005023815A2 (en) 2003-09-03 2004-08-31 Neuroprotective bicyclic compounds and methods for their use

Publications (1)

Publication Number Publication Date
PL1664050T3 true PL1664050T3 (pl) 2016-08-31

Family

ID=34272894

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04782733T PL1664050T3 (pl) 2003-09-03 2004-08-31 Neuroprotekcyjne związki bicykliczne i zawierające je kompozycje farmaceutyczne

Country Status (9)

Country Link
US (2) US8067425B2 (https=)
EP (1) EP1664050B1 (https=)
JP (1) JP4842817B2 (https=)
DK (1) DK1664050T3 (https=)
ES (1) ES2564803T3 (https=)
HU (1) HUE028528T2 (https=)
PL (1) PL1664050T3 (https=)
SI (1) SI1664050T1 (https=)
WO (1) WO2005023815A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002011676A2 (en) 2000-08-04 2002-02-14 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
EP1648873A4 (en) * 2003-03-20 2008-06-25 Neuren Pharmaceuticals Ltd NEUROPROTECTIVE MACROCYLIC COMPOUNDS AND METHODS OF THEIR APPLICATION
EP1622633B1 (en) 2003-05-15 2016-02-24 Ampio Pharmaceuticals, Inc. Treatment of t-cell mediated diseases
WO2008063311A2 (en) * 2006-10-11 2008-05-29 Neuren Pharmaceuticals Limited Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals
US8519127B2 (en) * 2003-09-03 2013-08-27 Mike John Bickerdike Cyclic glycyl-2-allyl proline and its use in treatment of peripheral neuropathy
US8791117B2 (en) * 2003-09-03 2014-07-29 Neuren Pharmaceuticals Limited Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals
EP2300011A4 (en) 2008-05-27 2012-06-20 Dmi Life Sciences Inc THERAPEUTIC PROCESSES AND COMPOUNDS
US9891219B2 (en) * 2008-10-10 2018-02-13 Mayo Foundation For Medical Education And Research Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive
US7928233B2 (en) * 2009-02-10 2011-04-19 Hoffmann-La Roche Inc. Spiroindolinone pyridine derivatives
CA2810844C (en) 2010-09-07 2017-03-21 Dmi Acquisition Corp. Diketopiperazine compositions for the treatment of metabolic syndrome and related conditions
SG10201608087WA (en) 2011-10-10 2016-11-29 Ampio Pharmaceuticals Inc Implantable medical devices with increased immune tolerance, and methods for making and implanting
EP3721884A1 (en) 2011-10-10 2020-10-14 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease with da-dkp (= aspartyl-alanyl diketopiperazine)
CN103841974A (zh) 2011-10-28 2014-06-04 安皮奥制药股份有限公司 鼻炎的治疗
JP6465803B2 (ja) * 2012-10-22 2019-02-06 シティ・オブ・ホープCity of Hope Etp誘導体
CA2906864A1 (en) 2013-03-15 2014-09-18 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
EP3024463B1 (en) 2013-07-25 2020-03-25 Neuren Pharmaceuticals Limited Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders
CA2958080A1 (en) 2014-08-18 2016-02-25 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
KR20240155382A (ko) 2016-05-26 2024-10-28 가부시키가이샤 아미노 압 수면 개선제
EP3512520B1 (en) 2016-09-15 2023-06-21 City of Hope Dithio derivatives of epidithiodiketopiperazine (etp)
EP4663182A2 (en) 2018-03-16 2025-12-17 Scent Science International Inc. Prophylactic or therapeutic agent for hypoxic injury, ischaemia-reperfusion injury and inflammation, cell protection agent for transplantation, and bio-preservation agent
CN112423774A (zh) * 2018-05-15 2021-02-26 L·H·L·特兰 用于治疗轻度认知障碍、抑郁和心理障碍的治疗剂组成及使用方法
CA3158406A1 (en) 2019-10-22 2021-04-29 Neuren Pharmaceuticals Limited Bicyclic compounds and methods for their use in treating pitt hopkins syndrome
GEAP202316350A (en) * 2021-02-12 2023-10-25 Neuren Pharmaceuticals Ltd Treatments of prader-willi syndrome
JP2024545685A (ja) * 2021-12-17 2024-12-10 ザ シージーピー ラボ リミテッド Cgpの動物、真菌及び海洋供給源、並びに疾患管理のための、並びに非神経学的及び/又は神経学的状態の治療のための増大したcgp濃度
WO2025088052A1 (en) * 2023-10-26 2025-05-01 Rousselot Bv Cyclic analogue of glycine-proline for use in the prevention and/or treatment of medical implant-related fibrosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH469006A (de) * 1965-07-07 1969-02-28 Sandoz Ag Verfahren zur Herstellung neuer synthetischer Alkaloide
CA2121724A1 (en) * 1993-04-21 1994-10-22 Toshifumi Watanabe Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction
US7202279B1 (en) * 1998-02-11 2007-04-10 Georgetown University Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders
AU2002340465A1 (en) * 2001-11-09 2003-05-19 Neuronz Biosciences, Inc. Cyclo(prolyl-glycine) and methods of use to treat neural disorders
US7232798B2 (en) * 2001-11-13 2007-06-19 Tran Loi H Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
AU2002363800A1 (en) 2001-11-13 2003-05-26 Loi Tran Therapeutic agent composition and method of use
EP1648873A4 (en) * 2003-03-20 2008-06-25 Neuren Pharmaceuticals Ltd NEUROPROTECTIVE MACROCYLIC COMPOUNDS AND METHODS OF THEIR APPLICATION

Also Published As

Publication number Publication date
EP1664050B1 (en) 2015-12-09
EP1664050A2 (en) 2006-06-07
JP2007504235A (ja) 2007-03-01
WO2005023815A3 (en) 2005-07-21
WO2005023815A2 (en) 2005-03-17
SI1664050T1 (sl) 2016-04-29
HUE028528T2 (en) 2016-12-28
US8067425B2 (en) 2011-11-29
US20060258663A1 (en) 2006-11-16
JP4842817B2 (ja) 2011-12-21
DK1664050T3 (en) 2016-03-07
ES2564803T3 (es) 2016-03-29
US20070197511A1 (en) 2007-08-23
US7776876B2 (en) 2010-08-17

Similar Documents

Publication Publication Date Title
SI1664050T1 (sl) Nevroprotektične biciklične spojine in farmacevtski sestavki, vsebujoči le-te
IL173639A (en) Ppar-activating compound and pharmaceutical composition containing same
IL174128A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
IL173602A0 (en) Heteroarylaminosulfonylphenyl derivatives and pharmaceutical compositions containing the same
IL173627A0 (en) 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives and pharmaceutical compositions containing the same
IL170758A0 (en) 7-amino-isoindolyl compounds and their pharmaceutical uses
IL173051A0 (en) N-glucoside derivatives and pharmaceutical compositions containing the same
EP1594508A4 (en) NEW BICYCLIC COMPOUNDS AND ASSOCIATED COMPOSITIONS
AU2003291103A8 (en) Pharmaceutical composition
IL171997A0 (en) Pyrrolodihydroisoquinoline derivatives and pharmaceutical compositions containing the same
IL175214A0 (en) 2-cyanopyrrolidinecarboxamide derivatives and pharmaceutical compositions containing the same
IL190017A0 (en) Bicyclic compounds and pharmaceutical compositions containing the same
IL165388A0 (en) Macrolide compounds and pharmaceutical compositions containing the same
IL164547A0 (en) Pharmaceutical composition
GB0300427D0 (en) Pharmaceutical composition
IL172159A0 (en) 2-oxo-pyridine derivatives and pharmaceutical compositions containing the same
AU2003250372A8 (en) Pharmaceutical composition
IL174249A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
GB0307866D0 (en) Pharmaceutical composition
EP1699458A4 (en) PHARMACEUTICAL COMPOSITION
PL378011A1 (pl) Proszkowe kompozycje farmaceutyczne
IL176077A0 (en) 1-n-phenyl-amino-1h-imidazole derivatives and pharmaceutical compositions containing them
GB0300885D0 (en) Pharmaceutical composition
ZA200601232B (en) 3-Aryl-4-hydroxyfuranone compounds and pharmaceutical and veterinary compositions containing them
GB0307869D0 (en) Pharmaceutical composition